| Document |
Document Title |
|
WO/2020/109720A1 |
The invention relates to a process for producing lithium bis(fluorosulfonyl)imide salt. The present invention discloses a process for producing lithium bis(fluorosulfonyl)imide salt involving the following steps: a) a step of producing b...
|
|
WO/2020/104634A1 |
This invention relates to compounds of general formula: wherein R0A and R0B are independently selected from hydrogen and pharmaceutically acceptable cations; and RA and RB are identical and selected from amide, carbamate, sulphonamide, a...
|
|
WO/2020/102901A1 |
Provided herein are synthetic compounds useful for inhibiting bacterial growth and uses thereof. Also provided are pharmaceutical compositions. The compounds and pharmaceutical compositions are useful for inhibiting growth of a bacterium...
|
|
WO/2020/102576A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2020/102574A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2020/091054A1 |
The invention provides a novel production method for an isoquinoline-6-sulfonamide derivative that is useful as a medicinal drug, and also provides an intermediate for use in the method. The invention is the 1,4-diazocane compound repres...
|
|
WO/2020/084854A1 |
The fluorinated imide salt compound of the present invention is a compound represented by general formula (1). In general formula (1), m is 1 or 2, n is an integer of 1-4, α is 1 or 2, and Xα+ represents an α-valent metal ion, a prima...
|
|
WO/2020/086728A1 |
In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured (Formula A) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2020/081999A1 |
The present invention relates to compounds of formula (I)-(VI) and/or (A)-(H-I), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer. The compounds of the present disclosure are useful in modulating ...
|
|
WO/2020/074403A1 |
The present invention relates to small molecule compounds capable of modulating appetite in a vertebrate animal, particularly in a mammal. The invention further relates to the use of the compounds of the invention in methods of treatment...
|
|
WO/2020/072605A1 |
The disclosure provides ionizable amine lipids and salts thereof (e.g., pharmaceutically acceptable salts thereof) useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepa...
|
|
WO/2020/063854A1 |
Disclosed are a class of quinoline-based derivatives and the use thereof in the preparation of a medicament for treating diseases related to VAP-1, and specifically disclosed are a compound represented by formula (II) and a pharmaceutica...
|
|
WO/2020/067398A1 |
The purpose of the present invention is to provide: a novel compound that inhibits cell invasion of filovirus; a medicinal composition that comprises the compound; an anti-filovirus agent or an inhibitor for cell invasion of filovirus; a...
|
|
WO/2020/061367A1 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
WO/2020/051099A1 |
The invention is concerned with the compounds of formula (I) and formula (II): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of using the compounds of formula (I) and formula (II) as...
|
|
WO/2020/050215A1 |
Provided for the purpose of efficient oxide production is a method for producing an oxide by oxidation of a starting compound in the presence of oxygen, characterized in that the starting compound is oxidized in the presence of manganese...
|
|
WO/2020/041301A1 |
Compounds, methods of use, and processes for making inhibitors of complement factor D or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the ...
|
|
WO/2020/035466A1 |
The present invention relates to compounds of formula (I): wherein A, B, X, Y, R1, R4 and R7 are as defined in the specification. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical ...
|
|
WO/2020/031836A1 |
A polymerizable ionic liquid according to the present invention includes a compound comprising: an anion that has a predetermined structure and that includes a perfluoroalkyl group and a polymerizable functional group in the molecule the...
|
|
WO/2020/027150A1 |
A compound represented by general formula (I) (wherein each symbol is as defined in the description) or a salt thereof has a potent neural protecting and/or repairing effect and, therefore, is usable as a therapeutic agent for neurologic...
|
|
WO/2020/016427A1 |
The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection an...
|
|
WO/2020/018944A1 |
In one aspect, the present disclosure provides methods of inhibiting STAT3 in a cell comprising contacting the cell with a compound of the formula: (I) wherein the variables are as defined herein. In another aspect, the present disclosur...
|
|
WO/2020/010140A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2020/006177A1 |
Disclosed herein are small molecule Vascular Adhesion Protein- 1 (VAP-1) modulator compositions, pharmaceutical compositions, the use and preparation thereof.
|
|
WO/2019/241851A1 |
The present invention relates to compounds that have the ability to inhibit lysine biosynthesis via the diaminopimelate pathway in certain organisms. As a result of this activity these compounds can be used in applications where inhibiti...
|
|
WO/2019/229357A1 |
The present invention relates to a process for preparing a compound of formula (III):: R2-(SO2)-N Li-(SO2)-F, said process comprising: - a step b) comprising: a step b1) of fluorination of a compound of following formula (I): R1-(SO2)-NH...
|
|
WO/2019/229359A1 |
The present invention concerns a method for preparing a compound of the following formula (III): R2-(SO2)-NM-(SO2)-F (III) in which R2 represents one of the following radicals: F, CF3, CHF2, CH2F, C2HF4, C2H2F3, C2H3F2, C2F, C3F7, C3H4F3...
|
|
WO/2019/232384A1 |
Compounds that may selectively inhibit Oplophorus luciferase-derived bioluminescent complexes, e.g., NanoBiT® bioluminescent complex, are disclosed as well as compositions and kits comprising the compounds, and methods of using the comp...
|
|
WO/2019/226490A1 |
Provided is a compound of Formula (I), wherein the variable groups are defined herein.
|
|
WO/2019/226643A1 |
Described herein are methods and compositions for treating a spinal injury. Aspects of the invention relate to administering to a subject an agent that upmodulates KCC2. Another aspect of the invention relates to administering to a subje...
|
|
WO/2019/215291A1 |
A compound of formula (I) or a pharmaceutically acceptable salt thereof.The compound is useful in therapy, e.g. for the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase4 or 2 (Nox4o...
|
|
WO/2019/210215A1 |
The present invention provides new prodrugs of therapeutically active loop diuretics, including oligomeric prodrugs, and compositions to treat medical disorders, for example, ocular disorders such as glaucoma, a disorder or abnormality r...
|
|
WO/2019/208721A1 |
Provided is a hair moisturizer comprising: a hydrolyzed protein; an amino acid derivative or a hydrolyzed protein derivative in which at least part of the active hydrogen of an amino group of an amino acid chosen from the group consistin...
|
|
WO/2019/206072A1 |
Provided is a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, wherein R 1, R 2, R 3, R 4, n and A are as defined in the specification and claims. Further provided are a preparation method for the compound ...
|
|
WO/2019/204614A1 |
Compounds as STAT3 inhibitors are described. A pharmaceutical composition comprising the same, methods of making the same, and a method for treating or preventing conditions such as cancer, chronic inflammation, and fibrosis using the sa...
|
|
WO/2019/193159A1 |
The present invention relates to bumetanide derivatives of formula (I) as well as pharmaceutical compositions comprising these compounds for use in the treatment or prevention of diseases/disorders involving Na+- K+- 2CI- - cotransporter...
|
|
WO/2019/193161A1 |
The present invention relates to bumetanide derivatives of formula (I) as well as pharmaceutical compositions comprising these compounds for use in the treatment or prevention of neurological diseases/disorders involving Na+- K+- 20Γ - ...
|
|
WO/2019/188200A1 |
Provided is a production method for a lithium sulfamate. The production method for a lithium sulfamate is characterized by including a step (1) for reacting a compound (1) that is represented by general formula (1) (in which X is fluorin...
|
|
WO/2019/172184A1 |
Provided is a metal imide complex which has a stable structure and is able to be easily synthesized, while being capable of efficiently oxidizing various substrates. A metal imide complex which contains a metal and an imide that serves a...
|
|
WO/2019/166633A1 |
The present invention relates to compounds of formula (I) : (I) wherein Q is selected from O or S; R1 is an optionally substituted hydrocarbyl group which may optionally include one or more heteroatoms N, O or S in its carbon skeleton, p...
|
|
WO/2019/166621A1 |
The present invention relates to phenylsulfonylureas and phenylsulfonylthioureas, wherein the phenyl ring is substituted either (i) at the ortho-position with a halo group, or (ii) at the meta- and para-positions, and wherein the group a...
|
|
WO/2019/166623A1 |
The present invention relates to phenylsulfonylureas and phenylsulfonylthioureas, wherein the phenyl ring is substituted with a monovalent group comprising either (i) an aryl or a heteroaryl group, or (ii) a nitrogen-containing heterocyc...
|
|
WO/2019/166608A1 |
The presently claimed invention relates to a color developer, a process for its manufacture and its use as a component in heat sensitive recording material. The heat sensitive recording material is useful for thermographic printing.
|
|
WO/2019/167949A1 |
The present invention addresses the problem of providing a method for producing a high-purity bis(fluorosulfonyl)amide alkali metal salt powder, wherein the reduction of the yield due to pyrolysis etc., is inhibited. The method for produ...
|
|
WO/2019/165232A1 |
Inhibitors of Glycerol 3-Phosphate Acyltransferase (GPAT) are provided; and methods of use in the treatment of cancer; and treatment of conditions relating to metabolic syndrome and hyperlipidemia.
|
|
WO/2019/160037A1 |
The purpose of the present invention is to provide methods for producing a carboxamide compound, a sulfonamide compound, and an ester compound using an acid halide. The methods for producing a carboxamide compound, a sulfonamide compound...
|
|
WO/2019/153088A1 |
A composition for oral administration comprising a cannabinoid in combination with a stilbenoid or derivative thereof and a solubility enhancing agent is described. Oral dosage forms, in the form of dissolvable tablet or capsule with enh...
|
|
WO/2019/154795A1 |
The present invention relates to 3-(benzylamino)-4-(cyclohexylamino)-N-(2-(piperazin-1-yl)eth
yl)benzenesulfonamide derivatives and related ferrostatin-1 (Fer-1) analogues as cell death inhibitors by inhibition of ferroptosis and/or oxyt...
|
|
WO/2019/152536A1 |
The present disclosure relates to compounds that are capable of modulating the WNT/Beta-Catenin pathway. The disclosure further relates to methods of treating colorectal cancer and other WNT/Beta-Catenin mediated cancers.
|
|
WO/2019/130866A1 |
Provided is an active ray- or radiation-sensitive resin composition which has excellent storage stability and can enable a pattern with excellent LWR performance to be obtained. Also provided are a resist film, a pattern forming method, ...
|
